Paul H. Lange - Concepedia

Author

Paul H. Lange

University of Washington

Also Known As

P H Lange, P Lange, PAUL H. LANGE, Paul H Lange, Paul H. Lange, Paul Henry Lange, Paul Lange, Paul. H. Lange

458

Publications

19.5K

Citations

H-Index

162

Concepts

All Affiliations

University of Washington University of Minnesota Medical Center University of Minnesota Fred Hutch Cancer Center University of Washington Medical Center

About

Paul H. Lange is an author at University of Washington specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	103	7.8K
2	Public Health	10	10	1.2K
3	Health Sciences	7	7	349
4	Engineering	4	4	554
5	Natural Sciences	1	1	16

Paul H. Lange

185

Publications

18.2K

Citations

H-Index

Page 1

	Year	Citations
Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease William J. Catalona, Alan W. Partin, Kevin M. Slawin, JAMA	1998	1.2K
Prostate Cancer James L. Mohler, Robert R. Bahnson, Barry Boston, Journal of the National Comprehensive Cancer Network	2010	897
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer Akash Kumar, Ilsa M. Coleman, Colm Morrissey, Nature Medicine Disease HeterogeneityMetastatic Prostate CancerUrologyGenitourinary CancerTumor Heterogeneity	2016	743
Screening for Prostatic Carcinoma with Prostate Specific Antigen Michael K. Brawer, Michael Chetner, Jeanette Beatie, The Journal of Urology	1992	624
The Value of Serum Prostate Specific Antigen Determinations Before and after Radical Prostatectomy Paul H. Lange, Cesar J. Ercole, Deborah J. Lightner, The Journal of Urology	1989	524
Kidney Cancer Robert J. Motzer, Neeraj Agarwal, Clair J. Beard, Journal of the National Comprehensive Cancer Network	2009	470
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016 Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Journal of the National Comprehensive Cancer Network Preclinical TherapeuticsNccn Guidelines InsightsPopulation Health SciencesGynecology OncologyOncology	2016	341
Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical Treatment Mark S. Soloway, Joseph V. Briggman, Gennaro A. Carpinito, The Journal of Urology	1996	339
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging William J. Catàlona, Paula C. Southwick, Kevin M. Slawin, Urology UrologyCancer DetectionCancer ScreeningMedicineBiostatistics	2000	334
LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics Holly M. Nguyen, Robert L. Vessella, Colm Morrissey, The Prostate	2017	307

Page 1